Olyos announces two strategic international acquisitions: NewScience, the market leader in Chili and reference player in health supplements across Latin America, and Somatoline, a leading dermo-cosmetics brand in Italy. These two acquisitions are completed only six months after Motion Equity Partners raised a €215m continuation fund to support the ambitious plan of one of its flagship investments.
With more than 75 years of history, Olyos is now a leading international platform in natural health and nutrition, built around its two key brands, Granions and Drasanvi that are distributed in pharmacies & parapharmacies and online. The Group has established itself as a strategic partner for pharmacists, a channel that represents nearly 80% of its sales. Olyos has become the 5th French pharmacy laboratory and the most dynamic player in the health supplements market (+34% sell-out growth in 2025). Alongside a double-digit organic growth sustained for more than five years, the Group is pursuing an ambitious and targeted M&A strategy, with six strategic acquisitions completed since 2020.
In June 2025, Motion Equity Partners raised a €215m continuation fund to support Olyos in a new phase of international development, with the ambition of positioning the Group among the top 10 European players in natural health and nutrition by 2030. Only six months after the closing, Olyos acquired NewScience, the Chilean leader in health supplements (~20% market share) and a recognized player in Latin America, with around €20m annual sales. Already present in the region through Drasanvi (market leader in Costa Rica and established player in Peru and Nicaragua), the Group is therefore significantly expanding its footprint in Iberian-speaking markets. This acquisition will accelerate the regional roll-out of Drasanvi, with NewScience products being integrated under the Drasanvi brand, and will firmly establish Olyos as a major player in the Latin American market.
In February 2026, Olyos reached another milestone with the acquisition of Somatoline in Italy. Somatoline is a legacy brand, highly renowned in the Italian market, positioned on premium dermo-cosmetics, health supplements and OTC products. The brand stands out for its very strong brand awareness among consumers and a broad distribution in more than 3,600 pharmacies and parapharmacies, with strong scientific credibility among pharmacists. While primarily active in Italy, Somatoline is also distributed in France, Spain, Belgium, Greece and Switzerland through local partners. This acquisition provides a strategic platform to accelerate the roll out of Olyos model in Italy, Europe’s largest market. Already present in Italy through one of its subsidiaries, the Group is now scaling up by leveraging Somatoline’s strong market position and broad geographical coverage to accelerate its expansion. This acquisition will enable the introduction and development of Granions products within the Italian market, while opening diversification opportunities into adjacent dermo-cosmetics segments.
Ultimately, the two acquired ranges, Somatoline and NewScience, will be respectively fully integrated under Granions and Drasanvi brands, the Group’s international umbrella brands. With the integration of NewScience and Somatoline, Olyos now exceeds the €200m sales threshold, structured around its two global brands. With 675 employees worldwide, Olyos is further strengthening its footprint in Southern Europe and Latin America, reaching a new scale as a structured international player able to deploy its high-performing commercial model across all its key geographies.
“Since 2020, Olyos has experienced very strong organic growth, driven by a deep strategic transformation carried out with Motion EP. In a resilient VMS market with structural growth of 5-7%, we have built one of the most efficient commercial models in the market: now a Top 5 pharmacy laboratory, a leader in the most dynamic segments, and the growth leader in pharmacies. Our ambition is to keep replicating this model across all our key geographies. After NewScience, the acquisition of Somatoline marks a structuring step in our strategy for the Granions brand: by combining our leadership in slimming health supplements with Somatoline’s dermo-cosmetics expertise, we are building a distinctive global offering for healthcare professionals and consumers” said Thierry Verne, CEO of Olyos.
“These acquisitions mark a decisive milestone in the Group’s trajectory. We anticipate many commercial and operational synergies. Olyos is successfully pursuing a precise and selective external growth strategy, with a well-filled pipeline of targeted acquisitions for the coming years” commented Jonathan Bienfait, Deputy CEO of Olyos.
“Olyos’ performance is remarkable. In just six months, the Group is already significantly ahead of its strategic plan. Significant development opportunities lie ahead, we are only at the beginning of this new phase of value creation’” added Patrick Eisenchteter, Managing Partner at Motion Equity Partners.
“These two acquisitions fully align with Olyos’ ongoing international development, significantly strengthening its presence in Southern Europe and Latin America. These particularly dynamic and high-potential markets offer ideal conditions to bring forth a global reference player. With two strong umbrella brands, Granions and Drasanvi, Olyos now has a unique platform to accelerate its growth, consolidate a still-fragmented market and continue building an international champion in natural health and nutrition” concluded Anthony Baudoin, Partner at Motion Equity Partners.
